Year None20212020201920182017 Sep 08, 2021 Tenaya Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates Aug 31, 2021 Tenaya Therapeutics to Present at Morgan Stanley 19th Annual Global Healthcare Conference Aug 03, 2021 Tenaya Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares Jul 29, 2021 Tenaya Therapeutics Announces Pricing of Upsized Initial Public Offering Jul 13, 2021 Tenaya Therapeutics Unveils Preclinical Research Supporting Product Candidate for Rare and Prevalent Heart Disease Indications at ESC Heart Failure 2021 Jun 30, 2021 Tenaya Therapeutics Announces New Appointments to Leadership Team May 20, 2021 Tenaya Therapeutics Receives Orphan Drug Designation and Presents Pre-Clinical Data for its Most Advanced Gene Therapy Product Candidate for Genetic Hypertrophic Cardiomyopathy Mar 01, 2021 Tenaya Therapeutics Secures $106 Million in Series C Funding to Accelerate Pipeline of Potentially Curative Therapies for Heart Disease
Sep 08, 2021 Tenaya Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates
Aug 31, 2021 Tenaya Therapeutics to Present at Morgan Stanley 19th Annual Global Healthcare Conference
Aug 03, 2021 Tenaya Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
Jul 13, 2021 Tenaya Therapeutics Unveils Preclinical Research Supporting Product Candidate for Rare and Prevalent Heart Disease Indications at ESC Heart Failure 2021
May 20, 2021 Tenaya Therapeutics Receives Orphan Drug Designation and Presents Pre-Clinical Data for its Most Advanced Gene Therapy Product Candidate for Genetic Hypertrophic Cardiomyopathy
Mar 01, 2021 Tenaya Therapeutics Secures $106 Million in Series C Funding to Accelerate Pipeline of Potentially Curative Therapies for Heart Disease
